Dr. Hiroshi Abbott

Radiation oncologist · Royal Marsden · United Kingdom (GB) · Oncology

Tier 3STK-0035GoodOwner MSL RARachel Adeyemi

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC, NSCLC
Scientific interests: irAE management
Engagement preference: Virtual
Advisory boards: 1
Publications: 3
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 18 Jan 2026 (240 days ago)
Next planned contact: 18 Jan 2027
Last 6 months vs target: 0%
0 of 1 expected engagements

Insights from this stakeholder (0)

No insights captured from engagements with this stakeholder.

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
18 Jan 2026	Advisory board	In person	Rachel Adeyemi	Vantrexa	PD-L1 testing turnaroundChemotherapy-free first line+1	0	—	Reviewed	ENG-0037

Timeline

18 Jan 2026
Advisory board
PD-L1 testing turnaround, Chemotherapy-free first line, Elderly / ECOG 2 patients

Related stakeholders (7)

Royal Marsden

Dr. Liam Quinn
Thoracic medical oncologist
Tier 1
Dr. Mariana Rossi
Pathologist
Tier 3
Dr. Daniel Weber
Community nephrologist
Tier 1
Dr. Zoë Jensen
Community nephrologist
Tier 2
Dr. Rosa Rossi
Renal pathologist
Tier 2
Dr. Valentina Xu
Headache specialist
Tier 3
Dr. Ximena Fischer
Primary care physician
Tier 1